Vanessa Biotech has registered VR-AD-1005, a novel antidiarrheal investigational drug, with the Pan African Clinical Trials Registry system.
The drug will be studied for the innovative treatment of severe diarrhea of cholera, heralding a pipeline of drugs developed in hopes of neutralizing the lethal diarrhea of cholera as well as rotaviral diarrhea and traveler’s diarrhea.